Here's how I see it, without drama. With XXII, you have a company with no revenue, great patents, and a management that seems to be a little bit in disarray. For their initial revenue stream, they plan to distribute upscale products to specialty shops in an industry where advertising is forbidden and existing customers are notoriously brand loyal. Ahem.
China is a crapshoot, who knows what goes on there. I'm guessing that the ruling claque profits handsomely from a piece of whatever tobacco action is going on and that existing relationships are not crazy about an upstart company taking some of their market share. The idea that the government there is concerned about the health of the populace is plausible, opening the door to reduced potency cigarettes, although the level of pollution and working conditions there renders this questionable.
As far as the FDA is concerned, are they subject to lobbying like other regulatory agencies? I have no idea, but how happy is Big Tobacco with a company that has a product that will wean smokers from their habit?
Medical MJ, will be great, smoking cessation will be great, opening the door to Asia will be great, all down the line, however, in my opinion. Since I have a lot invested in upcoming call options, Jan. and April, I hope I have this exactly wrong.
News 
Market Data 
Discover 
AI
